Nerve growth factor and brain-derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers. (Articolo in rivista)

Type

• Articolo in rivista (Classe)
• Prodotto della ricerca (Classe)

Label

• Nerve growth factor and brain-derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers. (Articolo in rivista) (literal)

Anno

• 2006-01-01T00:00:00+01:00 (literal)

Alternative label

• Del Porto F.a, Aloe L.b, Lagana B., Triaca V.c, Nofroni I., D'Amelio R. (2006)
  Nerve growth factor and brain-derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers.
  in Annals of the New York Academy of Sciences
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Del Porto F.a, Aloe L.b, Lagana B., Triaca V.c, Nofroni I., D'Amelio R. (literal)

Pagina inizio

• 438 (literal)

Pagina fine

• 443 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

• Impact Factor = 1.93 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 1069 (literal)

Rivista

• Annals of the New York Academy of Sciences (Rivista)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• a = Cattedra e U.O.C di Allergologia, Immunologia Clinica e Reumatologia, II Facoltà di Medicina e. Chirurgia, Università La Sapienza, Ospedale Sant'Andrea, Via di Grottarossa 1035-1039, 00189 Roma, Italy; b,c = Istituto di Neurobiologia e Medicina Molecolare del CNR, Via del Fosso di Fiorano, 64, 00143 Roma, Italy. (literal)

Titolo

• Nerve growth factor and brain-derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers. (literal)

Abstract

• Twenty consecutive rheumatoid arthritis (RA) patients (mean age 50.4 +/- 10.5 years; 17 females; mean disease duration 5.78 +/- 3.75 years) enrolled for tumor necrosis factor-alpha (TNF-alpha) blockers therapy (10 infliximab and 10 etanercept) were selected. Before starting therapy, 3 and 6 months thereafter all patients were evaluated for disease activity score (DAS), erythrocyte sedimentation rate (ESR), serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF). After 3 and 6 months a significant reduction in DAS, ESR, CRP, and IL-6 was observed, whereas no significant differences of NGF and BDNF serum levels were found. These preliminary results confirm that TNF-alpha blockers significantly improve disease activity and inflammation in RA; nevertheless further studies are needed to explain the mechanisms regulating NGF and BDNF release in RA patients treated with TNF-alpha blockers. (literal)

Prodotto di

• Istituto di neurobiologia e medicina molecolare (INMM) (Istituto)
• Funzioni del S.N./Neurotrofine (SV.P16.007.001) (Modulo)

Autore CNR

• LUIGI ALOE (Unità di personale interno)
• VIVIANA TRIACA (Unità di personale esterno)

Incoming links:

Prodotto

• Istituto di neurobiologia e medicina molecolare (INMM) (Istituto)
• Funzioni del S.N./Neurotrofine (SV.P16.007.001) (Modulo)

Autore CNR di

• LUIGI ALOE (Unità di personale interno)
• VIVIANA TRIACA (Unità di personale esterno)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Annals of the New York Academy of Sciences (Rivista)